FATE

Fate Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↑ 6/10
  • Momentum↑ 7/10
Fate Therapeutics sales and earnings growth
FATE Growth
Good
  • Revenue Y/Y↓ -46.92%
  • EPS Y/Y↑ 19.39%
  • FCF Y/Y↑ 13.00%
Fate Therapeutics gross and profit margin trends
FATE Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -2187.10%
  • ROIC↓ -40.10%
Fate Therapeutics net debt vs free cash flow
FATE Risk
Great
  • Debt / Equity↓ 0.3
  • Debt / FCF↓ 0.2
  • Interest coverage↓ NA

Fate Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗